Verici Dx plc reaches a global licensing and commercialization agreement with Thermo Fisher Scientific

Agreement grants rights to further develop an assay for pre-transplant prognostic testing.

Cardiff, U.K. (November 15, 2023) – Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced that it has signed an exclusive global licensing agreement with Thermo Fisher Scientific, the world leader in serving science, to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.

Read the full press release >